Core Viewpoint - Weijian Pharmaceutical, a leading Chinese pharmaceutical company specializing in kidney and blood diseases, has submitted its listing application to the Hong Kong Stock Exchange, showcasing strong revenue growth and a robust product pipeline [1][10]. Group 1: Company Overview - Weijian Pharmaceutical has over 20 commercialized drugs and one candidate drug, focusing on the treatment of kidney and blood diseases, with the largest number of commercialized original research drugs in China for kidney disease [1]. - The company has demonstrated strong financial performance, with a compound annual growth rate (CAGR) of 12.8% in revenue from 2022 to 2024, and a significant acceleration in growth in the first half of 2025, reaching 119.8% [1][10]. - Adjusted EBITDA for the years 2023 to the first half of 2025 is projected to be 0.32 billion, 1.12 billion, and 1.79 billion respectively, with profit margins increasing from 3.61% to 22.46% [1]. Group 2: Product and Market Focus - The company focuses on three main disease areas: kidney diseases, respiratory and infectious diseases, and blood diseases, with kidney disease products being the primary revenue source [2]. - In the first half of 2025, revenue shares from these three disease areas are 37.6%, 25.1%, and 19.9% respectively, with other products contributing 17.4% [2]. - Key products for kidney diseases include Gaiyouping, Kewpeiwei, Keliroluo, and Naisbao, with Kewpeiwei being the first FDA-approved targeted therapy for CKD-aP [4]. Group 3: Commercialization and Sales Network - Weijian Pharmaceutical has a strong commercialization capability, with sales of Keliroluo increasing from approximately 500,000 boxes in 2017 to about 7.5 million boxes in 2024, a 14-fold increase [4]. - The company's distribution network covers over 30 provinces and municipalities in China, reaching more than 10,000 hospitals and over 60,000 retail pharmacies [4]. - The company has a growing number of distributors, with 260 distributors in the first half of 2025, an increase of 94 from 2022 [5]. Group 4: Industry Outlook - The Chinese CKD treatment market is expected to maintain double-digit growth, with a projected market size of 25.1 billion in 2024 and a CAGR of 11.3%, reaching 82.5 billion by 2035 [6]. - The market for treating secondary hyperparathyroidism (CKD-SHPT) is also growing, with Weijian holding a 15.9% market share in the calcium mimetics segment [8]. - The blood disease treatment market is also expanding, with a projected market size of 3.9 billion by 2035, driven by increasing incidence rates [8]. Group 5: Competitive Advantages - Weijian Pharmaceutical's diverse product portfolio and strong market position in kidney and blood diseases provide a competitive edge, with several products expected to accelerate commercialization and revenue growth [9]. - The company has established strong partnerships and a robust academic network, supporting its clinical development and regulatory approval processes [5]. - The company's financial strength, with cash equivalents of 479 million as of June 2025, positions it well for future acquisitions and growth opportunities [5].

Core Viewpoint - Weijian International Holdings Group Limited (Weijian Pharmaceutical) has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor. The company is noted for having the largest number of commercialized original drugs for kidney diseases among Chinese pharmaceutical companies [1][4]. Company Overview - Weijian Pharmaceutical is a leading comprehensive pharmaceutical company in China, focusing on the treatment of kidney and blood diseases. The company integrates drug development, production, and commercialization, aiming to address significant clinical needs in these areas [4]. - The product portfolio includes over 20 commercialized drugs and one candidate drug, with a focus on chronic kidney disease (CKD) and blood diseases, which affect a large patient population [4][5]. - All major products have been commercialized in mainland China, except for one drug currently undergoing regulatory approval [4]. Financial Performance - Revenue for the years ending December 31 for 2022, 2023, and projected for 2024 is RMB 723.5 million, RMB 887.4 million, and RMB 901.8 million respectively [7][8]. - The company recorded losses of RMB 92.8 million in 2022 and RMB 17 million in 2023, but is projected to achieve a profit of RMB 8.57 million in 2024 [9]. - Gross profit for the same periods was RMB 369.0 million, RMB 502.6 million, and RMB 556.0 million, with gross margins of 51.0%, 56.6%, and 61.7% respectively [10][11]. Market Overview - China's healthcare expenditure has significantly increased from RMB 721.75 billion in 2020 to a projected RMB 950.75 billion in 2024, with a compound annual growth rate (CAGR) of 7.1% [12]. - The pharmaceutical market in China has grown from RMB 1,458.4 billion in 2020 to RMB 1,733.9 billion in 2024, with a CAGR of 4.4% [12]. - The CKD drug market in China is expected to grow from RMB 16.3 billion in 2020 to RMB 25.1 billion in 2024, with a CAGR of 11.3% [17].